Linaclotide vs Plecanatide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicLinaclotidePlecanatide
What it is

A guanylate cyclase-C agonist that the label says acts locally on the lining of the intestine.1

A guanylate cyclase-C agonist and structural analogue of uroguanylin that the label says acts locally on the lining of the intestine.3

FDA status

FDA-approved

FDA-approved as Linzess1,2

FDA-approved. Drugs@FDA lists Linzess with an original approval date of August 30, 2012. The label carries a boxed warning about serious dehydration in children younger than 2.1,2

Is linaclotide FDA-approved?

FDA-approved

FDA-approved as Trulance3,4

FDA-approved. Drugs@FDA lists Trulance with an original approval date of January 19, 2017. The label carries a boxed warning about serious dehydration in children.3,4

Is plecanatide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

Not among the six peptides the policy lists.5

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial Two randomized, double-blind, placebo-controlled trials in irritable bowel syndrome with constipation (NCT00948818 and NCT00938717), with 800 and 804 adults evaluated for efficacy.1
  • Large randomized human trial Two randomized, double-blind, placebo-controlled trials in chronic idiopathic constipation, with 642 and 630 adults evaluated for efficacy.1
  • Controlled human trial A 12-week randomized, double-blind, placebo-controlled trial in 328 children aged 6 to 17 with functional constipation.1

Large randomized human trials

  • Large randomized human trial Two 12-week randomized, double-blind, placebo-controlled trials in chronic idiopathic constipation that randomized 905 and 870 adults.3
  • Large randomized human trial Two 12-week randomized, double-blind, placebo-controlled trials in irritable bowel syndrome with constipation in which 699 and 754 adults received plecanatide or placebo.3
Records collected

15 ClinicalTrials.gov records and 49 PubMed records collected

12 ClinicalTrials.gov records and 16 PubMed records collected

Area of study

Gut and digestion1

Gut and digestion3

Latest dated events
  1. DailyMed publishes the Linzess label version cited on this page.1
  2. FDA approves a generic linaclotide application, according to Drugs@FDA.6
  3. FDA approves Linzess, according to Drugs@FDA.2
  1. DailyMed publishes the Trulance label version cited on this page.3
  2. FDA approves Trulance, according to Drugs@FDA.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    LINZESS (linaclotide) capsule · SPL version 39 · published 2026-06-01 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA202811 · original submission status AP · 2012-08-30 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    TRULANCE (plecanatide) tablet · SPL version 15 · published 2024-04-05 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  4. 4
    Drugs@FDA application NDA208745 · original submission status AP · 2017-01-19 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Drugs@FDA application ANDA209564 · original submission status AP · 2021-02-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026